GSK declares a big win with positive topline results for its adult RSV vaccine. But the jury still out on bottom line efficacy

Emma Walmsley’s bet on making GSK a pure play Big Pharma innovator just cleared a major milestone. But the GSK team is not home free yet. The global player announced that its adult RSV vaccine cleared a Phase III trial — AReSVi 006 — offering “exceptional protection” to 25,000 enrollees…

...

Click to view original post